Best Approach to Mild Pap Abnormalities?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

BETHESDA, Md--A new NCI study will evaluate three techniques to manage atypical squamous cells of undetermined significance that show up on Pap smears, including their cost effectiveness and acceptability to women.

BETHESDA, Md--A new NCI study will evaluate three techniques to manageatypical squamous cells of undetermined significance that show up on Papsmears, including their cost effectiveness and acceptability to women.

The trial will evaluate colposcopy; repeating Pap smears every six months;and human papillomavirus (HPV) testing as a means to differentiate betweenabnormalities that need immediate colposcopy and those that can best befollowed with repeat Pap tests at six-month intervals.

The study enrollment of 7,200 women with mild Pap test abnormalitiesshould be completed next year. Participants will be followed for threeyears. The study centers are the University of Alabama at Birmingham, Universityof Oklahoma, Magee-Womens Hospital, and the University of Washington.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content